Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. SPRING-2 is an ongoing phase 3, randomised, double-blind, active-...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet infectious diseases Vol. 13; no. 11; pp. 927 - 935
Main Authors:	Raffi, François, Jaeger, Hans, Quiros-Roldan, Eugenia, Albrecht, Helmut, Belonosova, Elena, Gatell, Jose M, Baril, Jean-Guy, Domingo, Pere, Brennan, Clare, Almond, Steve, Min, Sherene
Format:	Journal Article
Language:	English
Published:	London Elsevier Ltd 01.11.2013 Lancet Publishing Group Elsevier Limited
Subjects:	Adenine - administration & dosage Adenine - analogs & derivatives Adult Antiretroviral agents Antiviral agents CD4 Lymphocyte Count Dideoxynucleosides - administration & dosage Double-Blind Method Drug Administration Schedule Drug Combinations Female Heterocyclic Compounds, 3-Ring - administration & dosage HIV Infections - blood HIV Infections - drug therapy HIV Infections - virology HIV Integrase Inhibitors - administration & dosage HIV-1 - genetics HIV-1 - isolation & purification Human immunodeficiency virus 1 Humans Infectious Disease Infectious diseases Kaplan-Meier Estimate Lamivudine - administration & dosage Male Organophosphonates - administration & dosage Pharmacokinetics Pyrrolidinones - administration & dosage Raltegravir Potassium RNA, Viral - blood Tenofovir
ISSN:	1473-3099, 1474-4457, 1474-4457
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!